4-氟-2-硝基苯磺酰氯 | 568586-10-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氟-2-硝基苯磺酰氯
• 英文名称: 4-fluoro-2-nitrobenzene-1-sulfonyl chloride
• 英文别名: 4-fluoro-2-nitrobenzenesulfonyl chloride；4-fluoro-2-nitro-benzenesulfonyl chloride；4-fluoro-2-nitmbenzenesulfonyl chloride
• CAS: 568586-10-7
• 化学式: C₆H₃ClFNO₄S
• mdl: MFCD03618461
• 分子量: 239.612
• InChiKey: BHSUAEKACYUVJP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  88.3
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 海关编码：
  2904909090

反应信息

• 作为反应物：
  描述：

  4-氟-2-硝基苯磺酰氯 在 吡啶 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 H¹⁸F 、 sodium carbonate 、 potassium carbonate 、 4,7,13,16,21,24-六氧-1,10-二氮双环[8.8.8]二十六烷 作用下， 以 1,4-二氧六环 、 二甲基亚砜 、 乙腈 为溶剂， 反应 0.25h， 生成 4-氟-2-(氟-18)-N-[2-甲氧基-5-[4-(4-哒嗪基)-6-喹啉基]-3-吡啶基]苯磺酰胺
  参考文献：
  名称：

  [11C]GSK2126458 and [18F]GSK2126458, the first radiosynthesis of new potential PET agents for imaging of PI3K and mTOR in cancers

  摘要：

  GSK2126458 is a highly potent inhibitor of phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) with low picomolar to subnanomolar activity. [C-11]GSK2126458 and [F-18]GSK212 6458, new potential PET agents for imaging of PI3K and mTOR in cancer, were first designed and synthesized in 40-50% and 20-30% decay corrected radiochemical yield, and 370-740 and 37-222 GBq/lmol specific activity at end of bombardment (EOB), respectively. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.12.136
• 作为产物：
  描述：

  2,5-二氟硝基苯 在 1,3-二氯-5,5-二甲基海因 、 potassium carbonate 作用下， 以 水 、 溶剂黄146 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 5.0h， 生成 4-氟-2-硝基苯磺酰氯
  参考文献：
  名称：

  [11C]GSK2126458 and [18F]GSK2126458, the first radiosynthesis of new potential PET agents for imaging of PI3K and mTOR in cancers

  摘要：

  GSK2126458 is a highly potent inhibitor of phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) with low picomolar to subnanomolar activity. [C-11]GSK2126458 and [F-18]GSK212 6458, new potential PET agents for imaging of PI3K and mTOR in cancer, were first designed and synthesized in 40-50% and 20-30% decay corrected radiochemical yield, and 370-740 and 37-222 GBq/lmol specific activity at end of bombardment (EOB), respectively. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.12.136

文献信息

• [EN] OREXIN RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RÉCEPTEUR DE L'OREXINE
  申请人：HEPTARES THERAPEUTICS LTD

  公开号：WO2014006402A1

  公开（公告）日：2014-01-09

  The disclosures herein relate to novel compounds of formula wherein W, X and Y1, Y2, Y3 and Y4 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of neurological or psychiatric disorders associated with orexin receptors.

  本公开涉及一种新型化合物的公式，其中W、X和Y1、Y2、Y3和Y4在此处定义，并其在治疗、预防、改善、控制或减少与促觉素受体相关的神经系统或精神障碍的风险中的用途。
• Novel Sulfonaminoquinoline Hepcidin Antagonists
  申请人：Buhr Wilm

  公开号：US20120214803A1

  公开（公告）日：2012-08-23

  The present invention relates to novel hepcidin antagonists, pharmaceutical compositions comprising them and the use thereof as medicaments for the use in the treatment of iron metabolism disorders, such as, in particular, iron deficiency diseases and anemias, in particular anemias in connection with chronic inflammatory diseases.

  本发明涉及新型肝铁蛋白拮抗剂，包括它们的药物组合物以及将其用作药物治疗铁代谢紊乱，特别是铁缺乏病和贫血等疾病，特别是与慢性炎症性疾病相关的贫血。
• PNA monomer and precursor
  申请人：——

  公开号：US20030195332A1

  公开（公告）日：2003-10-16

  This application relates to monomers of the general formula (I) for the preparation of PNA (peptide nucleic acid) oligomers and provides method for the synthesis of both predefined sequence PNA oligomers and random sequence PNA oligomers: 1 wherein R1, R2, R3, R4, R5 is independently H, halogen, C 1 -C 4 alkyl, nitro, nitrile, C 1 -C 4 alkoxy, halogenated C 1 -C 4 alkyl, or halogenated C 1 -C 4 alkoxy, wherein at least one of R1, R3, and R5 is nitro; R6 is H or protected or unprotected side chain of natural or unnatural &agr;-amino acid; and B is a natural or unnatural nucleobase, wherein when said nucleobase has an exocyclic amino function, said function is protected by protecting group which is labile to acids but stable to weak to medium bases.

  这个应用程序涉及通式（I）的单体，用于制备PNA（肽核酸）寡聚体，并提供了合成预定义序列PNA寡聚体和随机序列PNA寡聚体的方法：其中R1、R2、R3、R4、R5独立地为H、卤素、C1-C4烷基、硝基、腈基、C1-C4烷氧基、卤代C1-C4烷基或卤代C1-C4烷氧基，其中至少有一个R1、R3和R5为硝基；R6为H或天然或非天然α-氨基酸的保护或未保护侧链；B为天然或非天然核碱基，当所述核碱基具有外环氨基功能时，所述功能由对酸敏感但对弱到中等碱稳定的保护基保护。
• [EN] METHODS OF TREATING LIVER DISEASES<br/>[FR] MÉTHODES DE TRAITEMENT DE MALADIES HÉPATIQUES
  申请人：ZAFGEN INC

  公开号：WO2014071368A1

  公开（公告）日：2014-05-08

  The invention provides tricyclic compounds and their use in treating liver disorders, such as non-alcoholic steatohepatitis and related disorders (e.g., fibrosis). The compounds are contemplated to have activity against methionyl aminopeptidase 2.

  这项发明提供了三环化合物及其在治疗肝病方面的用途，如非酒精性脂肪性肝炎和相关疾病（如纤维化）。这些化合物被认为具有对蛋氨酸氨肽酶2的活性。
• Chiral Nitroarenes as Enantioselective Single-Electron-Transfer Oxidants for Carbene-Catalyzed Radical Reactions
  作者：Hongling Wang、Yuhuang Wang、Xingkuan Chen、Chengli Mou、Shuyan Yu、Huifang Chai、Zhichao Jin、Yonggui Robin Chi

  DOI：10.1021/acs.orglett.9b02736

  日期：2019.9.20

  A new class of chiral oxidants is developed. These readily accessible oxidants contain a nitro group for oxidation and a chiral sulfonamide moiety for stereoselectivity control. The chiral information from the oxidants can effectively transfer to the substrates in carbene-catalyzed β-hydroxylation of enals via single-electron-transfer radical processes. We expect these oxidants to find unique applications

  新型的手性氧化剂被开发出来。这些容易获得的氧化剂包含用于氧化的硝基和用于立体选择性控制的手性磺酰胺部分。来自氧化剂的手性信息可通过单电子转移自由基过程在卡宾催化的烯类的β-羟基化反应中有效转移至底物。我们希望这些氧化剂能在其他不对称氧化和氧原子转移反应中找到独特的应用。